Brief: Frequency Therapeutics Releases New Data From Two FX-322 Clinical Studies Plans To Advance Single-Dose Regimen

Korro Bio

23/03/2021 11:10

March 23 (Reuters) - Frequency Therapeutics Inc  FREQ.O :
    * FREQUENCY THERAPEUTICS RELEASES NEW DATA FROM TWO FX-322
CLINICAL STUDIES; PLANS TO ADVANCE SINGLE-DOSE REGIMEN
    * FREQUENCY THERAPEUTICS INC - INTERIM FX-322 PHASE 2A
RESULTS
SHOW FOUR INJECTION SCHEDULE HAD NO DISCERNIBLE HEARING BENEFIT
    * FREQUENCY THERAPEUTICS INC - SEPARATE FX-322 PHASE 1B
STUDY
CONFIRMS HEARING IMPROVEMENT FROM SINGLE INJECTION
    * FREQUENCY THERAPEUTICS INC - NO TREATMENT-RELATED SERIOUS
ADVERSE EVENTS WERE OBSERVED IN FX-322 PHASE 2A STUDY

Source text for Eikon:  ID:nBw485v0la 
Further company coverage:  FREQ.O 

 ((Reuters.Briefs@thomsonreuters.com;))